STOCK TITAN

Network-1 Technologies, Inc. - NTIP STOCK NEWS

Welcome to our dedicated page for Network-1 Technologies news (Ticker: NTIP), a resource for investors and traders seeking the latest updates and insights on Network-1 Technologies stock.

Network-1 Technologies, Inc. (NYSE American: NTIP) specializes in the development, licensing, and protection of intellectual property (IP) rights. The company collaborates with inventors and patent owners to facilitate the development and monetization of patented technologies. Currently, Network-1 owns 102 U.S. patents and 15 international patents, covering various telecommunications, data networking technologies, document stream operating systems, and media content identification technologies.

Network-1's strategy focuses on acquiring and investing in high-quality patents with significant licensing potential. It actively pursues licensing opportunities for its intellectual property assets. Its core patent portfolios include the Cox, M2M/IoT, HFT, Mirror Worlds, and Remote Power patents. Notably, the Remote Power Patent has generated over $188 million in licensing revenue since May 2007, while the Mirror Worlds Patent Portfolio has brought in $47.15 million to date.

Network-1 continues to expand its patent portfolio. The recent issuance of U.S. Patent No. 11,916,893 enhances its M2M/IoT Patent Portfolio, which now includes 37 issued U.S. patents and several pending applications. These patents cover enabling technologies for eSIMs, 5G network authentication, and modern Internet transport layer security solutions.

Financially, Network-1 reported a net revenue of $2.601 million for the year ended December 31, 2023, primarily from litigation settlements related to its Remote Power Patent. Despite a net loss of $1.457 million, the company's robust cash position of $43.394 million and marketable securities of $43.067 million ensure sufficient liquidity for future operations.

In addition to its core business, Network-1 has a significant investment in ILiAD Biotechnologies, LLC, owning approximately 6.8% of the clinical-stage biotechnology firm. ILiAD's BPZE1 vaccine for whooping cough has shown promising results in Phase 2b clinical trials.

Network-1 also implements a Share Repurchase Program and a consistent dividend policy. The company has repurchased over 9.72 million shares since the program's inception and continues to pay semi-annual cash dividends of $0.05 per share.

News
Rhea-AI Summary
Network-1 Technologies, Inc. declares semi-annual cash dividend of $0.05 per common share
Rhea-AI Impact
Rhea-AI Sentiment
End-of-Day
0.43%
Tags
dividends
-
Rhea-AI Summary
ILiAD Biotechnologies reports positive results in Phase 2b Human Challenge study of BPZE1 vaccine against whooping cough
Rhea-AI Impact
Rhea-AI Sentiment
End-of-Day
-- %
Tags
-
Rhea-AI Summary
Network-1 Technologies receives new patent for key derivation technology for embedded SIM cards, part of a comprehensive patent portfolio for IoT and M2M devices.
Rhea-AI Impact
Rhea-AI Sentiment
End-of-Day
0.92%
Tags
none
News
Rhea-AI Summary
Rhea-AI Impact
Rhea-AI Sentiment
End-of-Day
-0.9%
Tags
-
Rhea-AI Summary
Rhea-AI Impact
Rhea-AI Sentiment
End-of-Day
-2.21%
Tags
buyback
-
Rhea-AI Summary
Rhea-AI Impact
Rhea-AI Sentiment
End-of-Day
2.21%
Tags
Rhea-AI Summary

Network-1 Technologies (NYSE: NTIP) reported financial results for the year ending December 31, 2022, showing no revenue, a stark contrast to $36 million from settlements in 2021. The company incurred a net loss of $2.3 million or $0.10 per share, down from a net income of $14.3 million or $0.59 per share in the previous year. Despite the losses, Network-1 holds $48.4 million in cash and marketable securities, indicating sufficient liquidity for future operations. Key developments included $43 million financing for ILiAD Biotechnologies, resulting in an unrealized gain of $3.9 million. The company repurchased 228,530 shares of its stock for approximately $531,000 in 2022.

Rhea-AI Impact
Rhea-AI Sentiment
End-of-Day
-0.92%
Tags
-
News
Rhea-AI Summary

Network-1 Technologies (NYSE American: NTIP) has declared a semi-annual cash dividend of $0.05 per common share, payable on March 31, 2023, to shareholders on record as of March 15, 2023. This announcement aligns with the company's dividend policy, which is periodically reviewed by its Board of Directors and may change based on various factors, including earnings and financial requirements. Network-1 is engaged in developing and licensing intellectual property, holding 97 U.S. patents across telecommunications and data networking technologies. The company has generated over $187 million in licensing revenue from its Remote Power Patent since May 2007.

Rhea-AI Impact
Rhea-AI Sentiment
End-of-Day
-- %
Tags
dividends
-
Rhea-AI Summary

Network-1 Technologies, Inc. (NYSE American: NTIP) announced the issuance of U.S. Patent No. 11,575,381 by the U.S. Patent and Trademark Office, enhancing its HFT Patent Portfolio. This patent pertains to advanced technologies in high-frequency trading using field-programmable gate array hardware, which is crucial for reducing transaction latency. The portfolio now includes nine issued patents and two pending applications, with patent terms extending to 2039. Network-1 focuses on monetizing its intellectual property, which has previously generated significant licensing revenue, including over $187 million from the Remote Power Patent.

Rhea-AI Impact
Rhea-AI Sentiment
End-of-Day
-2.25%
Tags
none
News
Rhea-AI Summary

Network-1 Technologies, Inc. (NTIP) reported no revenue for the quarter and nine months ended September 30, 2022, down from $17 million and $35.7 million in the same periods of 2021. The decline was primarily due to the absence of prior year litigation settlements. Net income decreased to $2.2 million ($0.09 per share) for Q3 2022 from $6.6 million ($0.28 per share) in Q3 2021. For the nine months, NTIP recorded a net loss of $618,000 compared to a profit of $15.3 million in 2021. The company maintains a strong cash position of $48.9 million. It initiated several legal actions for patent infringement during October and November 2022.

Rhea-AI Impact
Rhea-AI Sentiment
End-of-Day
-0.89%
Tags

FAQ

What is the current stock price of Network-1 Technologies (NTIP)?

The current stock price of Network-1 Technologies (NTIP) is $1.28 as of November 4, 2024.

What is the market cap of Network-1 Technologies (NTIP)?

The market cap of Network-1 Technologies (NTIP) is approximately 29.7M.

What does Network-1 Technologies, Inc. do?

Network-1 Technologies, Inc. specializes in the development, licensing, and protection of intellectual property rights.

What are Network-1's core business areas?

Network-1 focuses on acquiring, developing, licensing, and monetizing patented technologies, particularly in telecommunications, data networking, document stream operating systems, and media content identification.

What are Network-1's most notable patents?

Network-1's most notable patents include the Remote Power Patent and the Mirror Worlds Patent Portfolio, which have generated significant licensing revenue.

How much revenue has Network-1's Remote Power Patent generated?

The Remote Power Patent has generated over $188 million in licensing revenue since May 2007.

What financial condition is Network-1 in?

As of March 31, 2024, Network-1 had cash and cash equivalents and marketable securities worth $43.394 million, ensuring sufficient liquidity for future operations.

Does Network-1 pay dividends?

Yes, Network-1 pays semi-annual cash dividends of $0.05 per share, amounting to $0.10 per share annually.

What is the Share Repurchase Program?

Network-1's Share Repurchase Program allows the company to repurchase up to $5 million of its common stock over a 24-month period. Over 9.72 million shares have been repurchased since the program's inception.

What recent achievements has Network-1 made?

Recent achievements include the issuance of new patents in its M2M/IoT Patent Portfolio and financial gains from litigation settlements related to its Remote Power Patent.

What is Network-1's investment in ILiAD Biotechnologies?

Network-1 holds approximately 6.8% of ILiAD Biotechnologies, LLC, a clinical-stage biotech company developing a vaccine for whooping cough.

Where is Network-1 Technologies, Inc. located?

Network-1 Technologies, Inc. is headquartered at 445 Park Ave, New York, New York, United States.

Network-1 Technologies, Inc.

NYSE:NTIP

NTIP Rankings

NTIP Stock Data

29.72M
23.04M
40.76%
24.74%
0.01%
Specialty Business Services
Patent Owners & Lessors
Link
United States of America
NEW CANAAN